Pharmacokinetics and Tolerability of Zavesca (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses

Trial Profile

Pharmacokinetics and Tolerability of Zavesca (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2016

At a glance

  • Drugs Miglustat (Primary)
  • Indications Gangliosidoses
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 May 2016 New trial record
    • 18 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top